بالأسفل التجارب السريرية الحالية.
غربل قائمة الدراسات هذه بالموقع والحالة وغيرها.
Rochester, Minn.
The purpose of this study is to estimate the event-free survival (EFS) distribution for newly-diagnosed patients with BRAFV600-mutant high-grade glioma (HGG) without H3 K27M mutations excluding anaplastic pleomorphic xanthoastrocytoma (aPXA) and anaplastic ganglioglioma (aGG) treated with radiation therapy followed by a maintenance combination of dabrafenib and trametinib and to compare this EFS to contemporary historical controls.
The purpose of this study is to evaluate the long-term safety and tolerability of NBI-921352 when administered for up to 106 weeks. Also, to investigate the effect of NBI-921352 on long-term seizure control.
The purpose of the study is to learn more about adolescent and young adults' experience with chronic pain. In particular, we are studying factors which lead to pain-associated disability and factors which predict decreased disability during and after participation in a three-week intensive treatment program. In addition to gathering information from the young people with chronic pain, parents are also asked to give their perspective.
The purpose of this study is to understand the role of systemic inflammation in the genesis of seizures in susceptible children by gaining a clearer understanding of the spectrum of inflammatory responses that occur in healthy children post-vaccinations.
The purpose of this study is to assess the ability of the hyperphagia questionnaires to identify children and young adults with early-onset obesity for genetic testing to identify variants in 36 genes of interest associated with MC4R pathway genetic obesity
The purpose of this study is to systematically and prospectively record accurate and complete data regarding the clinical presentation, treatment, and outcomes of patients diagnosed with RB; collect, bank, preserve, and analyze biomaterials from patients with RB, and to correlate phenotypic data with findings from human biomaterials.
تساهم التبرّعات، وهي قابلة للخصم الضريبي، في دعم آخر التطورات في الأبحاث وطرق الرعاية لإحداث نقلة نوعية في الطب.